3.78
0.03 (0.80%)
| Previous Close | 3.75 |
| Open | 3.76 |
| Volume | 733,697 |
| Avg. Volume (3M) | 915,984 |
| Market Cap | 258,630,624 |
| Price / Book | 1.25 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2025 - 3 Mar 2025 |
| Diluted EPS (TTM) | -2.18 |
| Total Debt/Equity (MRQ) | 16.86% |
| Current Ratio (MRQ) | 8.91 |
| Operating Cash Flow (TTM) | -105.21 M |
| Levered Free Cash Flow (TTM) | -61.14 M |
| Return on Assets (TTM) | -35.22% |
| Return on Equity (TTM) | -64.68% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Care Facilities (US) | Bearish | Mixed |
| Medical Care Facilities (Global) | Bearish | Mixed | |
| Stock | COMPASS Pathways Plc - American | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.38 |
|
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360. |
|
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| % Held by Insiders | 22.15% |
| % Held by Institutions | 48.33% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 60.00 (HC Wainwright & Co., 1,487.30%) | Buy |
| Median | 18.00 (376.19%) | |
| Low | 12.00 (Maxim Group, 217.46%) | Buy |
| Average | 30.00 (693.65%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 4.75 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 01 Nov 2024 | 60.00 (1,487.30%) | Buy | 4.75 |
| Maxim Group | 01 Nov 2024 | 12.00 (217.46%) | Buy | 4.75 |
| RBC Capital | 01 Nov 2024 | 18.00 (376.19%) | Buy | 4.75 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 10 Jan 2025 | Announcement | Compass Pathways Announces Pricing of Underwritten Offering |
| 18 Dec 2024 | Announcement | Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI) |
| 25 Nov 2024 | Announcement | Compass Pathways to Participate in December Investor Conferences |
| 31 Oct 2024 | Announcement | Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates |
| 24 Oct 2024 | Announcement | Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |